Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis in solid organ transplant patients: A semiprospective multicenter study

Transplantation

Volumn 98, Issue 8, 2014, Pages 898-902

  Willinger, Birgit ^a   Lackner, Michaela ^b   Lass Flörl, Cornelia ^b   Prattes, Jürgen ^c   Posch, Verena ^c   Selitsch, Brigitte ^a   Eschertzhuber, Stephan ^b   Hönigl, Katharina ^c   Koidl, Christoph ^c   Sereinigg, Michael ^c   Raggam, Reinhard B ^c   Thornton, Christopher R ^d   Krause, Robert ^c   Hoenigl, Martin ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Aspergillosis; BAL; Galactomannan; Lateral Flow Device test; Solid organ transplantation

Indexed keywords

GALACTOMANNAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FUNGUS CULTURE; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LATERAL FLOW DEVICE TEST; LIVER TRANSPLANTATION; LUNG ASPERGILLOSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NONHUMAN; ORGAN TRANSPLANTATION; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; RAPID TEST; SENSITIVITY AND SPECIFICITY; SOLID ORGAN TRANSPLANTATION; YOUNG ADULT; ADOLESCENT; CROSS REACTION; HOSPITAL INFORMATION SYSTEM; INVASIVE PULMONARY ASPERGILLOSIS; MICROBIOLOGY; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; BRONCHOALVEOLAR LAVAGE FLUID; CROSS REACTIONS; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES;

EID: 84922069623     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000153     Document Type: Article

References (40)

1. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101.
2. Baddley JW, Stephens JM, Ji X, et al. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 2013; 13: 29.
3. Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Tr a n s p l I n f e c t D i s 2013; 15: 233.
4. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12: 220.
5. Yang CH, He XS, Chen J, et al. Fungal infection in patients after liver transplantation in years 2003 to 2012. Ann Transplant 2012; 17: 59.
6. Perkhofer S, Lass-Florl C, Hell M, et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocom-promised and/or immunosuppressed patients. Int J Antimicrob Agents 2010; 36: 531.
7. Bhaskaran A, Hosseini-Moghaddam SM, Rotstein C, et al. Mold infections in lung transplant recipients. Semin Respir Crit Care Med 2013; 34: 371.
8. Singh N, Suarez JF, Avery R, et al. Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis. J Infect 2013; 67: 72.
9. Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97: 351.
10. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373.
11. Lass-Florl C, Resch G, Nachbaur D, et al. The value of computed tomographyYguided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45: e101.
12. Seeber K, Duettmann W, Krause R, et al. Usefulness of the serum galactomannan assay for early response assessment and treatment stratifications of invasive aspergillosis. Curr Fungal Infect Rep 2012; 63: 198.
13. Hoenigl M, Salzer HJ, Raggam RB, et al. Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies. Med Mycol 2012; 50: 266.
14. Husain S, Clancy CJ, Nguyen MH, et al. Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of As-pergillus galactomannan antigen in bronchoalveolar lavage fluid. Clin Vaccine Immunol 2008; 15: 1760.
15. Pasqualotto AC, Xavier MO, Sanchez LB, et al. Diagnosis of invasive aspergillosis in lung transplant recipients by detection of galactomannan in the bronchoalveolar lavage fluid. Transplantation 2010; 90: 306.
16. Gerlinger MP, Rousselot P, Rigaudeau S, et al. False positive galactomannan Platelia due to piperacillin-tazobactam. Med Mal Infect 2012; 42: 10.
17. Mikulska M, Furfaro E, Del Bono V, et al. Piperacillin/tazobactam (TazocinTM) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012; 67: 1746.
18. Patterson TF. Risk stratification for invasive aspergillosis: early assessment of host susceptibility. Med Mycol 2009; 47(suppl 1): S255.
19. Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762.
20. Hoenigl M, Seeber K, Koidl C, et al. Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive asper-gillosis under antifungal prophylaxis and empirical therapy. Mycoses 2013; 56: 471.
21. Thornton CR. Development of an immunochromatographic lateral-flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15: 1095.
22. Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp 2012; 22: 61.
23. Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1-93)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vaccine Immunol 2009; 16: 1844.
24. White PL, Parr C, Thornton C, et al. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013; 51: 1510.
25. Held J, Schmidt T, Thornton CR, et al. Comparison of a novel As-pergillus lateral-flow device and the Platelia\galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. Infection 2013; 41: 1163.
26. Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 2012; 65: 588.
27. Azoulay E, Dupont H, Tabah A, et al. Systemic antifungal therapy in critically ill patients without invasive fungal infection∗. Crit Care Med 2012; 40: 813.
28. Wiederhold NP, Najvar LK, Bocanegra R, et al. Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on detection of invasive pulmonary aspergillo-sis. J Clin Microbiol 2013; 51: 459.
29. Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary asper-gillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012; 89: 120.
30. Bhaskaran A, Mumtaz K, Husain S. Anti-Aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15: 514.
31. Baddley JW, Andes DR, Marr KA, et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol 2013; 51: 128.
32. Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant recipients. Transplantation 2013; 96: 664.
33. Tofte N, Jensen C, Tvede M, et al. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients. Scand J Infect Dis 2012; 44: 835.
34. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080.
35. Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 2013; 57: 3262.
36. Hoenigl M, Raggam RB, Salzer HJ, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39: 510.
37. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50: 1258.
38. Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One 2012; 7: e43347.
39. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813.
40. Hoenigl M, Strenger V, Buzina W, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother 2012; 67: 2029.